Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
Norio Yasui-Furukori, Kojiro Hashimoto, Kazutoshi Kubo, Tetsu Tomita Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Until now there has been no information available on drug interaction between paliperidone and TS-1®, an oral an...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ca6b542bbbdb401981d02d6907e26979 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Norio Yasui-Furukori, Kojiro Hashimoto, Kazutoshi Kubo, Tetsu Tomita Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Until now there has been no information available on drug interaction between paliperidone and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative. The patient in the case presented here was a 39-year-old man with a 15-year history of schizophrenia. The patient's usual treatment of 2 mg/day of risperidone was changed to 3 mg/day of paliperidone extended release. He experienced worsening psychotic symptoms after switching from risperidone to paliperidone while he was also receiving TS-1. Retrospective analyses showed plasma concentration of paliperidone was consistently lower during the treatment with TS-1 than without TS-1. This case suggests there is drug interaction between paliperidone extended-release tablets and TS-1. Keywords: schizophrenia, antipsychotic, OROS, diarrhea, Positive and Negative Syndrome Scale |
|---|